Original reporting and analysis on the stories shaping biotech.
Novo Nordisk filed a federal lawsuit accusing Eli Lilly of running deceptive ads that make Zepbound and Mounjaro look superior by cherry-picking dose comparisons. In a market racing toward $100 billion, the fight over who gets to say "we're better" just landed in court.
Allogene's ALLO-316 just did what no off-the-shelf CAR-T therapy has done before: produce durable remissions in metastatic solid tumors. The Phase 1 data, published in the Journal of Clinical Oncology, could redraw the boundaries of cell therapy.
Crystalys just raised $130M to bring a gout drug already approved in five Asian countries to the U.S. With a competing therapy just rejected by the FDA and millions of American patients stuck with limited options, the timing couldn't be better.
ARPA-H just dropped $160 million on seven teams racing to make gene therapy work like a software platform: swap one piece of code, treat a whole new disease. If the aggressive timelines and novel regulatory models pan out, it could reshape how we think about curing the rarest genetic conditions.
J&J's OTTAVA just became the first table-integrated surgical robot to earn FDA authorization, creating an entirely new device category. After a decade of delays, billion-dollar lawsuits, and a $900 million write-down, the fight for Intuitive Surgical's robotic surgery throne just got real.
Leqembi just became the first Alzheimer's drug you can take entirely at home, from first dose to last. With nine-month clinic waitlists and infusion-center bottlenecks choking patient access, this FDA approval could reshape who actually gets treated.
GSK's partner Hansoh just delivered the first-ever Phase 3 survival win for a B7-H3 antibody-drug conjugate in small-cell lung cancer. In one of oncology's most competitive target races, being first to prove patients live longer is a powerful opening move.
Novartis's top-selling heart drug lost half its sales to generics in Q2 2026, yet the company beat profit estimates by 12%. The secret: cost discipline, surging cancer drugs, and a kidney disease strategy that's quietly becoming a competitive fortress.
The FDA just gave Dyne Therapeutics' Duchenne drug the fast lane, setting a January 2027 decision date. Z-rostudirsen produces roughly ten times more dystrophin than the current standard, and the functional data are turning heads.
No drug has ever worked against Stargardt disease, the most common inherited macular degeneration that robs teenagers of their central vision. Belite Bio's tinlarebant just became the first therapy to prove it can slow the damage in a pivotal Phase 3 trial, and the data is striking.
Novo Nordisk is suing Eli Lilly over weight-loss drug ads it calls deceptive, alleging Lilly cherry-picked outdated clinical data to make Zepbound look superior to Wegovy. The lawsuit could reshape how the two GLP-1 giants market their blockbuster drugs to millions of Americans.
Tempus AI is dropping $1.5 billion on Personalis to grab its cancer-detecting blood test and build the most vertically integrated oncology data platform in the industry. Wall Street's reaction? Both stocks fell 9%. The bull-bear debate is just getting started.
A most-wanted fugitive who vanished 20 years ago was just discovered working as chief medical officer of a NASDAQ-listed biotech. His fake résumé claimed Stanford, Harvard, and seven approved drugs. The real story exposes terrifying gaps in how the industry vets its leaders.
Abbott disclosed two cyberattacks in July 2026 while posting a strong $12.6 billion quarter. Hackers claim they stole 30 million records, including Social Security numbers and doctor-patient notes. Wall Street barely blinked, but should it have?
Former LifeMD employees allege clinicians had just two minutes per patient to prescribe powerful GLP-1 weight-loss drugs. The STAT News investigation puts Novo Nordisk's entire telehealth strategy under a harsh spotlight.
South Africa's Aspen Pharmacare just won Health Canada approval for a generic version of Ozempic, making Canada the first G7 country to greenlight copycat semaglutide. With nine generic applications under review and patents crumbling globally, Novo Nordisk's $26 billion franchise is facing its first real threat.
Samsung Biologics just dropped $1.8 billion on a Swiss peptide manufacturer, making the largest pharma M&A in South Korean history. The target: PolyPeptide Group, a company sitting on exactly what the GLP-1 boom desperately needs.
The Pentagon made flu shots optional for troops in April. By June, nearly 300 recruits at a Texas Air Force base were sick with influenza, one trainee died, and the military quietly started requiring the vaccine again.
A UC Berkeley spinout co-founded by Nobel laureate Jennifer Doudna wants to go public and fund a CRISPR therapy that could permanently lower cholesterol with a single infusion. The catch? It's entering one of biotech's most competitive battlefields with zero human data.
While 39 companies fight over GLP-1 obesity drugs, a freshly launched startup called Mwyngil Therapeutics just raised $60 million to bet on completely different biology. Their CEO says she's not interested in another me-too, and investors are listening.
Bristol Myers Squibb just bought NVIDIA's newest AI supercomputer, leapfrogging Lilly and Roche in pharma's escalating compute arms race. The real question: can a chip that costs more than most startups actually discover better drugs?
Pfizer's ecnoglutide and Innovent's mazdutide cleared a key hurdle toward China's national insurance formulary, potentially opening access to hundreds of millions of patients. But getting on the list means accepting the kind of price cuts that reshape entire business models.
Join thousands of biotech professionals who start their day with our free, daily briefing.